Y-mAbs Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Y-mAbs Therapeutics

04/03/2025 15:50

Y-mAbs Therapeutics Inc YMAB.OQ reported a quarterly adjusted loss of 15 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -2 cents.  The mean expectation of nine analysts for the quarter was for a loss of 12 cents per share. Wall Street expected results to range from -25 cents to -4 cents per share.

Revenue rose 13.4% to $26.50 million from a year ago; analysts expected $27.29 million.

Y-mAbs Therapeutics Inc's reported EPS for the quarter was a loss of 15 cents​.

The company reported a quarterly loss of $6.79 million.

Y-mAbs Therapeutics Inc shares had fallen by 33.7% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had fallen by about 9.2% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," 1 "hold" and 1 "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $20.50

This summary was machine generated from LSEG data March 4 at 03:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.12
-0.15
Missed
Sep. 30 2024
-0.16
-0.16
Met
Jun. 30 2024
-0.13
-0.21
Missed
Mar. 31 2024
-0.14
-0.15
Missed